Balaxi Pharmaceuticals Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023
For the nine months, sales was INR 1,814.61 million compared to INR 2,557.51 million a year ago. Revenue was INR 1,806.01 million compared to INR 2,586.09 million a year ago. Net loss was INR 133.21 million compared to net income of INR 378.62 million a year ago. Basic loss per share from continuing operations was INR 13.03 compared to basic earnings per share from continuing operations of INR 37.83 a year ago. Diluted loss per share from continuing operations was INR 12.92 compared to diluted earnings per share from continuing operations of INR 37.55 a year ago.